Aquinnah Pharmaceuticals Obtains $5,000,000 New Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=28d69f84-6a38-45b0-b505-ef3848a80e30
Date
12/22/2015
Company Name
Aquinnah Pharmaceuticals
Mailing Address
700 Main Street North Cambridge, MA 02139 USA
Company Description
Aquinnah Pharmaceutical’s approach is unique by integrating human genetic, human pathology and cellular biology R&D expertise, towards the development of a new therapeutic approach. Our approach has the potential to treat the majority of patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease.
Website
http://www.aquinnahpharma.com
Transaction Type
Venture Equity
Transaction Amount
$5,000,000
Transaction Round
Undisclosed
Proceeds Purposes
This funding adds further momentum to the numerous peer reviewed grants that we have received and will accelerate our program toward clinical development of new drugs for ALS and other neurodegenerative diseases.
M&A Terms
Venture Investor
Takeda Ventures